Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 33,093 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Not listed Phase 1 Interventional

Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis

NCT00411723
View directory record Official record
Conditions
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting
Interventions
RTL1000 (recombinant T cell receptor ligand), RTL1000 Placebo
Drug
Lead sponsor
Artielle ImmunoTherapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2009 · Synced Oct 23, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

Belimumab in Remission of VASculitis

NCT01663623
View directory record Official record
Conditions
Vasculitis
Interventions
Placebo, Belimumab 10 mg/kg, Azathioprine
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 23, 2026, 1:40 PM EDT
Active, not recruiting Phase 3 Interventional

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

NCT05881408
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
delandistrogene moxeparvovec, placebo
Genetic
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
Male only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 1:40 PM EDT
Completed Not applicable Interventional

Modification of Asthma With Soy Isoflavone

NCT00741208
View directory record Official record
Conditions
Asthma
Interventions
Soy Isoflavone
Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 23, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study

NCT02218008
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Colton, California • Garden Grove, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 23, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

NCT01475825
View directory record Official record
Conditions
Hypercholesterolemia, Heterozygous Familial
Interventions
mipomersen sodium 200 mg, Placebo, mipomersen sodium 70 mg
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
20
States / cities
Mission Viejo, California • Aurora, Colorado • Cooper City, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 23, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Transcutaneous Electrical Nerve Stimulation During Outpatient Endometrial Biopsy

NCT05472740
View directory record Official record
Conditions
Endometrial Diseases, Pain, Postoperative
Interventions
TENS 7000
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 23, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Aromatherapy on the Incidence and Severity of Acute Pain

NCT03122574
View directory record Official record
Conditions
Venipuncture
Interventions
Lavender Aromatherapy, Jojoba Aromatherapy
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
7 Years to 11 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 23, 2026, 1:40 PM EDT
Terminated Phase 3 Interventional Results available

Use of Tamsulosin to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

NCT01568918
View directory record Official record
Conditions
Postoperative Urinary Retention
Interventions
Tamsulosin hydrochloride, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 23, 2026, 1:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Targeted Assessment of Cognition and Tactical-performance With Ingested Ketones

NCT07771790
View directory record Official record
Conditions
Cognition
Interventions
KetoneIQ®, Placebo
Dietary Supplement
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 23, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

NCT01968213
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Rucaparib, Placebo
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Fullerton, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 23, 2026, 1:40 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis

NCT07213960
View directory record Official record
Conditions
FSGS
Interventions
APL2, Placebo
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 23, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19

NCT04988035
View directory record Official record
Conditions
COVID-19
Interventions
Danicopan, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Bakersfield, California • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 23, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))

NCT02729025
View directory record Official record
Conditions
Subjects With Hyperlipidemia, Dyslipidemia
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years to 80 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Miami, Florida • Las Vegas, Nevada • Mooresville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 23, 2026, 1:40 PM EDT
Withdrawn Phase 2 Interventional

Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes

NCT01477476
View directory record Official record
Conditions
Type I Diabetes
Interventions
Anakinra, Placebo Comparator
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 23, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

NCT02436668
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Ibrutinib, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
28
States / cities
Huntsville, Alabama • Avondale, Arizona • Daly City, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 23, 2026, 1:40 PM EDT
Terminated Phase 3 Interventional Results available

A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors

NCT00428597
View directory record Official record
Conditions
Carcinoma, Islet Cell, Carcinoma, Pancreas
Interventions
sunitinib malate, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
14
States / cities
Aurora, Colorado • Iowa City, Iowa • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2010 · Synced Oct 23, 2026, 1:40 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Interventions
Lepodisiran Sodium, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
17,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
222
States / cities
Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 171 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Single Doses of ILV-095 in Healthy Subjects

NCT00822835
View directory record Official record
Conditions
Healthy Subjects
Interventions
ILV-095, Placebo
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2009 · Synced Oct 23, 2026, 1:40 PM EDT
Terminated Phase 3 Interventional Results available

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

NCT03285308
View directory record Official record
Conditions
Gastroparesis, Diabetes Mellitus
Interventions
Placebo, Relamorelin
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
113
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 95 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 23, 2026, 1:40 PM EDT
Completed Phase 3 Interventional

Combined Pharmacotherapies for Alcoholism

NCT00768508
View directory record Official record
Conditions
Alcoholism
Interventions
Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy, Naltrexone 50 mg/day + Cognitive Behavioral Therapy, Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy, Placebo + Cognitive Behavioral Therapy
Drug · Other
Lead sponsor
Bankole Johnson
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 23, 2026, 1:40 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Radicle GI Health™ RFY: A Study Assessing the Impact of DAO Supplementation on Gastrointestinal and Other Histamine Intolerance Symptoms

NCT07835776
View directory record Official record
Conditions
GI Health
Interventions
Active GI Health Product 1, Placebo GI Health Control
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo

NCT01243450
View directory record Official record
Conditions
Acne
Interventions
Tretinoin, placebo
Drug
Lead sponsor
Spear Pharmaceuticals
Industry
Eligibility
12 Years to 40 Years
Enrollment
958 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Mountain Lakes, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 23, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

NCT01912391
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Selegiline, Placebo (for Selegiline)
Drug
Lead sponsor
Mood and Anxiety Research, Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 23, 2026, 1:40 PM EDT